Сhoice of RAAS blocker in the treatment of heart failure in acute myocarditis
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
https://orcid.org/0000-0003-0904-7406
Abstract
The aim – to evaluate the effectiveness of sacubitril/valsartan and enalapril in heart failure treatment in patients with acute severe myocarditis with reduced left ventricular ejection fraction based on dynamic analysis of the heart structural and functional changes.
Materials and methods. The study is based on the results of examinations of 90 patients with a severe course of acute myocarditis (AM) with reduced ejection fraction (EF) of the left ventricle (LV) – ≤40 %. The patients were divided into two groups: the 1st group included 48 patients who were treated with an angiotensin-converting enzyme (ACE) inhibitor – enalapril as part of heart failure (HF) therapy; the 2nd group included 42 patients with AM who received the sacubitril/valsartan combination instead of enalapril in the complex therapy of HF. All patients underwent a 6-minute walk test, echocardiography (EchoCG) with the speckle-tracking method, and cardiac magnetic resonance imaging (CMR). Examinations were carried out three times: in the 1st month from the onset of AM symptoms before the appointment of drug therapy, after 6 and 12 months of observation. Part of the patients from the 1st group, namely 25 patients (52.1 %) in whom the use of ACE inhibitors proved to be ineffective after six months, was transferred to the combination of sacubitril/valsartan (group 1A).
Results and discussion. After six months of treatment, compared to the 1st group, the patients of the 2nd group were distinguished by better indicators of the structural and functional state of the heart, which characterise the contractility and volume of the LV – the values of LV EF and LV longitudinal global systolic strain (LGSS) were higher by 13,7 and 26.2 % respectively, LV end-diastolic volume index (EDVi) was 13.2% lower, as well as a 21.7 % lower number of LV segments in which delayed contrast was detected on cardiac MRI. After six months of taking the sacubitril/valsartan combination in 1A group patients, an improvement in the structural and functional state of the heart was also achieved: the values of LVEF and LGSS increased by 19.2 % and 27.9 %, respectively, and LV EDVi decreased by 19.0 %; the number of LV segments in which delayed enhancement was determined on cardiac MRI decreased by 30.7 %. With the help of regression analysis, it was established the presence of a set of factors that determine the priority of prescribing the sacubitril/valsartan combination as initial therapy in patients with severe myocarditis: presence of reduced LVEF – ≤40 %; pronounced decrease in longitudinal and circular global LV strain – ≤8.5 and ≤9.0 %, respectively; pronounced dilatation of the LV – EDVi ≥102 ml/m2; presence of III or higher HF functional class; presence of delayed enhancement in ≥ 5,0 LV segments according to cardiac MRI data.
Conclusions. In patients with a severe course of myocarditis, the sacubitril/valsartan combination prescribed as initial therapy showed higher effectiveness compared to ACE inhibitors in terms of improving contractility and reducing LV dilatation, as well as improving the functional class of heart failure. A complex of factors has been established that prove the expediency of prescribing the sacubitril/valsartan combination as initial therapy for heart failure in patients with acute myocarditis.
Article Details
Keywords:
References
Kovalenko VM, Lutai MI, Sirenko YuM, Sychov OS, editors. Sertsevo-sudynni zakhvoriuvannia: klasyfikatsiia, standarty diahnostyky ta likuvannia. 6th ed. Kyiv: Chetverta khvylia; 2023. s. 159-64, 321-55. Ukrainian.
Kovalenko V M, Nesukay EG, Cherniuk SV, Kozliuk AS, Kirichenko RM. [Diagnosis and treatment of myocarditis. Recommendations of the Ukrainian Association of Cardiology]. Ukr J Cardiol. 2021 Sep. 9;28(3):67-88. https://doi.org/10.31928/1608-635X-2021.3.6788. Ukrainian.
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tschöpe C, Cooper LT Jr, Camici PG. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Circ Heart Fail. 2020;13:e007405. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007405.
Bolla GB, Fedele A, Faggiano A, Sala C, Santangelo G, Carugo S. Efects of Sacubitril/Valsartan on biomarkers of fbrosis and infammation in patients with heart failure with reduced ejection fraction. BMC Cardiovasc Disord. 2022; 22:217. https://doi.org/10.1186/s12872-022-02647-0.
Brociek E, Tymi´nska A, Giordani AS, Caforio AL, Wojnicz R, Grabowski M, Oziera´nski K. Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice. Biology. 2023;12:874. https://doi.org/10.3390/biology12060874.
Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: a position statement of the ESC Working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636-48. https://doi.org/10.1093/eurheartj/eht210.
Cemin R, Casablanca S, Foco L, Schoepf E, Erlicher A, Di Gaetano R, Ermacora D. Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology. J Clin Med. 2023;12:621. https://doi.org/10.3390/jcm12020621.
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-76. https://doi.org/10.1016/j.jacc.2018.09.072.
Gao Q, Yi W, Gao C, Qi T, Li L, Xie K, Zhao W, Chen W. Cardiac magnetic resonance feature tracking myocardial strain analysis in suspected acute myocarditis: diagnostic value and association with severity of myocardial injury. BMC Cardiovasc Disord. 2023;23(1):162. https://doi.org/10.1186/s12872-023-03201-2.
Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Prognostic value of cardiac magnetic resonance tissue characterisation in risk stratifying patients with suspected myocarditis. JACC. 2017;70(16):1964-76. https://doi.org/10.1016/j.jacc.2017.08.050.
Hernandez AV, Pasupuleti V, Scarpelli N, Malespini J, Banach M, Bielecka-Dabrowa AM. Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials. Arch Med Sci. 2023;3:565-76. https://doi.org/10.5114/aoms/159113.
Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 Expert consensus document on cardiovascular magnetic resonance: a report of the American college of cardiology foundation task force on the expert consensus documents. J Am Coll Cardiol. 2010; 55(23):2614-62. https://doi.org/10.1016/j.jacc.2009.11.011.
Hutt E, Kaur S, Jaber WA. Modern tools in cardiac imaging to assess myocardial inflammation and infection. Eur Heart J Open. 2023;3(2):oead019. https://doi.org/10.1093/ehjopen/oead019.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification in adults: an update from the American Society of echocardiography and European Asssociation of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1-38. https://doi.org/10.1016/j.echo.2014.10.003.
Liang W, Xie BK, Ding PW, Wang M, Yuan J, Cheng X, Liao YH, Yu M. Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway. Front Pharmacol. 2021;12:727838. https://doi.org/10.3389/fphar.2021.727838.
Mandoli GE, Cameli M, Pastore MC, Loiacono F, Righini FM, D’Ascenzi F, Focardi M, Cavigli L, Lisi M, Bisleri G, Dokollari A, Bernazzali S, Maccherini M, Valente S, Henein MY. Left ventricular fibrosis as a main determinant of filling pressures and left atrial function in advanced heart failure. Eur Heart J – Cardiovasc Imaging. 2024;25(4):446-53. https://doi.org/10.1093/ehjci/jead340.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-726. https://doi.org/10.1093/eurheartj/ehab368.
Shi YJ, Yang CG, Qiao WB, Liu YC, Dong GJ. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction. Eur J Pharmacol. 2023;961:176170. https://doi.org/10.1016/j.ejphar.2023.176170.
Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hübner N, Kelle S, Klingel K, Maatz H, Parwani AS, Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van Linthout S. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169-93. https://doi.org/10.1038/s41569-020-00435-x.
Tschöpe C, Diez J. Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. Eur Heart J. 2019;40:979-81. https://doi.org/10.1093/eurheartj/ehy307.
Zannad F, Ferreira JP. Is Sacubitril/Valsartan Antifibrotic? J Am Coll Cardiol. 2019;73(7):807-9. https://doi.org/10.1016/j.jacc.2018.11.041.
Zhang M, Zou Y, Li Y, Wang H, Sun W, Liu B. The history and mystery of sacubitril/ valsartan: From clinical trial to the real world. Front Cardiovasc Med. 2023;10:1102521. https://doi.org/10.3389/fcvm.2023.1102521.
Zile MR, O’Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019;73(7):795-806. https://doi.org/10.1016/j.jacc.2018.11.042.